Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership

Reuters

10/29

Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership

Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its "XingShi" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579973126"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579973126\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579973126?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 17:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579973126","market":"us","top_or_hot":-1,"title":"Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-29 17:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL7l9Wmt:1","article_id":"2579973126","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579973126","pubTimestamp":1761731804,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical  to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK0183":"MSCI概念","BK0188":"融资融券","BK4588":"碎股","BK4112":"金融交易所和数据","BK0012":"证金概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK0187":"一线龙头","BK0028":"国家队","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","00656":"复星国际","BK0175":"白马股","NDAQ":"纳斯达克OMX交易所","BK0060":"抗癌","BK1230":"工业集团企业","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","06086":"方舟健客","BK4585":"ETF&股票定投概念","BK0196":"行业龙头","BK1247":"药品零售","BK0239":"医药制造","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK0096":"民营医院","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"方舟与复星医药启动AI驱动的银屑病管理合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":0.9,"06086":0.9,"NDAQ":0.9},"content_text":"Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n    \n\n        Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}